VTGN - VistaGen Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

42.79M

Cash

9.622M

Avg Qtr Burn

-10.41M

Short % of Float

13.55%

Insider Ownership

0.79%

Institutional Own.

11.44%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Fasedienol (PH94B) Details Social Anxiety Disorder	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Itruvone, PH10 (pherine nasal spray ) Details Major depressive disorder	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PH94B (pherine nasal spray) (fasedienol) Details Adjustment Disorder	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PH80 ( nasal spray ) Details Menopause, Hot flashes	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AV-101(4-Cl-KYN) (targets the NMDAR) Details Major depressive disorder	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.